Jonathann Kuo, MD

Dr. Jonathann Kuo portrait with green background

Certifications

MD

Education

BA: Boston University
MD: Boston University
Residency: New York Presbyterian Hospital / Weill Cornell
Fellowship: New York Presbyterian Hospital / Hospital for Special Surgery / Memorial Sloan Kettering Cancer Center

Founder, CEO, & Medical Director

Jonathann Kuo, MD is a double Board-Certified Pain Management Specialist and Anesthesiologist. He is the founder of Hudson Health, an innovative healthcare system with four integrated practices: Hudson Medical for interventional regenerative pain management, Hudson Wellness for preventative wellness, Hudson Mind for interventional mental health, and Hudson Life for functional and longevity medicine.

Since opening Hudson in 2010, Dr. Kuo has treated over 50,000 patients. His dedication to patient care is matched by his steadfast contributions to clinical research. Having collaborated with renowned doctors and health organizations across the globe, Dr. Kuo has emerged as a prominent thought leader across the interventional pain management and orthobiologics fields.

In his spare time, Dr. Kuo is an accomplished artist who has exhibited at several galleries and displays many of his works across Hudson Health’s TriBeCa and West Village practices. He also enjoys biohacking, cycling, travel gastronomy, and spending time with his growing family.
Dr. Kuo graduated from the prestigious 7 year accelerated BA/MD program at Boston University. He then completed his training at one of New York’s top institutions, New York Presbyterian Hospital. He received additional fellowship training in Pain Management at Memorial Sloan Kettering Hospital and the Hospital for Special Surgery.
With Hudson Mind, Dr. Kuo has created a new specialty - Interventional Mental Health, which is a system to treat mental health disorders. The foundational treatments for this program include Dual Sympathetic blocks for PTSD and anxiety, Ketamine Infusions for chronic pain and depression, and Transcranial Magnetic Stimulation for depression and OCD.

Dr. Kuo firmly believes that numerous mental health conditions can be effectively managed by addressing and enhancing the fundamental biological systems within the body. By optimizing cellular metabolic health through the utilization of peptides, resetting the autonomic nervous system, rebalancing hormones, and implementing dietary and lifestyle adjustments, significant strides have been observed in improving mental health—all without the need for lifelong medication reliance.

Having administered over 2000 dual sympathetic blocks, Dr. Kuo is a pioneering voice in the growing interventional mental health field. Under his guidance and leadership, Hudson Mind facilitates research for upcoming studies on emerging interventions, including Psilocybin and MDMA.

Please read our white paper on this speciality HERE.

More about Dr. Kuo

Languages

English, Chinese (Mandarin), Chinese (Cantonese), Taiwanese

Hospital affiliation

North Shore / Long Island Jewish Hospital, Mt. Sinai / Beth Israel Medical Center

Research

Pulsed Radiofrequency-Enhanced Dual Sympathetic Block for the Treatment of Post-Traumatic Stress Disorder   https://www.cureus.com/articles/160880-pulsed-radiofrequency-enhanced-dual-sympathetic-block-for-the-treatment-of-post-traumatic-stress-disorder#!/metrics

Clinicial work and published papers

SGB for Anxiety

Research Paper

“SGB attenuates sympathetic outflow from the SG and provides anxiety symptom relief by restoring dysregulated SNS signaling. When used in conjunction with psychotherapy, SGBs have a 70%-80% success rate in treating anxiety and PTSD symptoms (16, 19-20).”
Stellate Ganglion Block for Long COVID

Research Paper

“The significant improvement of long COVID symptoms following bilateral SGBs described in these case studies indicate an important role of dysautonomia and cerebral blood flow in the pathophysiology of long COVID (16).”
SGB for PTSD

Clinical Trial

This study will enroll patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for post-traumatic stress disorder (PTSD). Following an initial screening visit, clinical assessment, and enrollment, subjects will be randomized into treatment and placebo arms.
fMRI evaluation of the effect of Stellate Ganglion Blocks for PTSD, in conjunction with NYU Langone and the Stella Center

Clinical Trial

A Randomized, Double Blind, Placebo-controlled Study of the Effects of Stellate Ganglion Block on Neural Activity and Symptoms in Participants With Post-traumatic Stress Disorder

Thought Leadership

Meet the Team

Dr. Marcel Green portrait with green background
Marcel Green, MD

Psychiatrist

Alessandra Fabris-Tantawi Cropped Portrait
Alessandra Fabris-Tantawi LMSW, M.Ed

Psychotherapist / Integrative Somatic Trauma Specialist

Tasha Ednie portrait with green background
Tasha Ednie

Operations Manager

Leigh Harlow portrait with green background
Leigh Harlow

TMS Technician & Operations Associate

Paula Lamanna bio pic with blurred background
Paula Lamanna, LCSW, CASAC

Clinical Social Work/Therapist